title: Early phase mixed chimerism in bone marrow does not affect long-term outcomes of myeloablative single-unit cord blood transplantation for adult patients with hematological malignancies.
abstract: Coexisting hematopoiesis from donor and recipient origin, called a mixed chimerism status, can occur in patients after myeloablative allogeneic hematopoietic stem cell transplantation. However, its impact on the outcomes of cord blood transplantation (CBT) has yet to be clarified. We retrospectively analyzed 150 adult patients who received myeloablative single-unit CBT for hematological malignancies in our institute. At the median time of first bone marrow analysis of 41 days after CBT, mixed chimerism was observed in 16 of the 150 patients. Among patients with mixed chimerism, 4 patients relapsed. The remaining 12 patients were alive and in remission at a median follow-up of 50 months. Bone marrow-mixed chimerism did not have a significant impact on the incidences of disease-free survival, relapse, or transplant-related mortality after CBT. These data show that early phase mixed chimerism did not have a significant impact on long-term outcomes after myeloablative single-unit CBT for hematological malignancies.
authors.affiliation: a Department of Hematology/Oncology , The Institute of Medical Science, The University of Tokyo , Tokyo , Japan.
authors.forename: Takaaki
authors.initials: T
authors.lastname: Konuma
authors.affiliation: a Department of Hematology/Oncology , The Institute of Medical Science, The University of Tokyo , Tokyo , Japan.
authors.forename: Seiko
authors.initials: S
authors.lastname: Kato
authors.affiliation: a Department of Hematology/Oncology , The Institute of Medical Science, The University of Tokyo , Tokyo , Japan.
authors.forename: Maki
authors.initials: M
authors.lastname: Oiwa-Monna
authors.affiliation: a Department of Hematology/Oncology , The Institute of Medical Science, The University of Tokyo , Tokyo , Japan.
authors.forename: Hiroto
authors.initials: H
authors.lastname: Ishii
authors.affiliation: a Department of Hematology/Oncology , The Institute of Medical Science, The University of Tokyo , Tokyo , Japan.
authors.forename: Arinobu
authors.initials: A
authors.lastname: Tojo
authors.affiliation: a Department of Hematology/Oncology , The Institute of Medical Science, The University of Tokyo , Tokyo , Japan.
authors.forename: Satoshi
authors.initials: S
authors.lastname: Takahashi
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001853:Bone Marrow; D036101:Cord Blood Stem Cell Transplantation / Q000009:adverse effects; D005260:Female; D006085:Graft Survival; D019337:Hematologic Neoplasms / Q000401:mortality* / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012008:Recurrence; D018183:Transplantation Chimera; D019172:Transplantation Conditioning / Q000009:adverse effects / Q000379:methods; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D055815:Young Adult
keywords: Bone marrow; cord blood transplantation; leukemia; lymphoma; mixed chimerism; myelodysplastic syndrome